Clinical Trials on Autosomal Dominant Osteopetrosis Type 2

Total 9626 results

Indiana University

Completed

Use of Low Dose Pioglitazone to Treat Autosomal Dominant Polycystic Kidney Disease (PIOPKD)

Polycystic Kidney Disease

United States
The Cleveland Clinic
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Pilot Study of Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Polycystic Kidney Diseases

United States
Zhi-Hong Liu, M.D.

Terminated

Randomized Clinical Trial of Triptolide Woldifii for Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney

China
National Institute of Neurological Disorders and...

Completed

MRI in Autosomal Dominant Partial Epilepsy With Auditory Features

Epilepsies, Partial

United States
Galapagos NV

Terminated

A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

Belgium, Netherlands, Italy, Spain, Czechia, Germany, Poland
Palladio Biosciences

Completed

The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease

United States
Otsuka Pharmaceutical Development & Commercialization...

Completed

Tolvaptan Extension Study in Participants With ADPKD (TEMPO 4/4)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

United States, Australia, Belgium, Germany, Italy, Poland, Romania, United Kingdom, Argentina, Canada, France, Netherlands, Russian Federation
Otsuka Pharmaceutical Co., Ltd.

Completed

A Study to Investigate the Long-term Safety and Efficacy of Tolvaptan in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Trial 156-04-251 in Japan]

Autosomal Dominant Polycystic Kidney Disease （ADPKD)

Japan
Otsuka Pharmaceutical Development & Commercialization...

Completed

8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (NOCTURNE)

Autosomal Dominant Polycystic Kidney Disease

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]

Autosomal Dominant Polycystic Kidney Disease

Japan
Shanghai Changzheng Hospital

Unknown

Triptolide-Containing Formulation as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

China
Yale University

Terminated

Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy

Autosomal Dominant Polycystic Kidney Disease

United States
Mayo Clinic

Completed

Pasireotide LAR in Severe Polycystic Liver Disease (SOM230)

Autosomal Dominant Polycystic Kidney Disease | Polycystic Liver Disease | Autosomal Dominant Polycystic Liver Disease | Somatostatin Analogs

United States
University of Texas Southwestern Medical Center

Withdrawn

Cross-over Pilot Study of Blood Cholesterol Response to Dietary Saturated Fat in Patients With Autosomal Dominant Hypercholesterolemia

Familial Hypercholesterolemia

United States
Palladio Biosciences
Centessa Pharmaceuticals plc

Terminated

Safety of Lixivaptan in Subjects Previously Treated With Tolvaptan for Autosomal Dominant Polycystic Kidney Disease (ALERT)

ADPKD | Polycystic Kidney Disease, Adult

United States
University of Cologne

Completed

Ketogenic Dietary Interventions in Autosomal Dominant Polycystic Kidney Disease (ADPKD) (Keto-ADPKD)

ADPKD

Germany
Otsuka Pharmaceutical Development & Commercialization...

Completed

Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Germany, Italy, Belgium, United Kingdom
Assistance Publique - Hôpitaux de Paris
Novartis

Completed

The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients (EVERKYSTE)

Autosomal Dominant Polycystic Kidney Disease

France
Azienda Ospedaliero-Universitaria Consorziale Policlinico...

Unknown

Metformin vs Tolvaptan for Treatment of Autosomal Dominant Polycystic Kidney Disease (METROPOLIS)

ADPKD

Italy
Changlin Mei
The First Affiliated Hospital with Nanjing Medical University; The First Affiliated... and other collaborators

Completed

Using Preimplantation Genetic Diagnosis in Autosomal Dominant Polycystic Kidney Disease Patients: a Multicenter Clinical Trial (ESPERANCE)

Polycystic Kidney, Type 1 Autosomal Dominant Disease

China
Otsuka Canada Pharmaceutical Inc.

Recruiting

Canadian Medical Assessment of JINARC™ Outcomes Registry (C-MAJOR)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Canada
University Hospital, Brest

Completed

Clinical and Molecular Description of PKD1 and PKD2 Mutation Negative Carriers in ADPKD (GeneQuest)

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

France
Mario Negri Institute for Pharmacological Research

Completed

Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency (ALADIN2)

Autosomal Dominant Polycystic Kidney Disease

Italy
Mayo Clinic
Polycystic Kidney Disease Foundation

Completed

Autosomal Dominant Polycystic Kidney Disease (ADPKD) Pain Study

Kidney, Polycystic, Autosomal Dominant

United States
The Rogosin Institute
Weill Medical College of Cornell University; New York Presbyterian Hospital

Withdrawn

Repository Study of Autosomal Dominant Polycystic Kidney Disease (Repository)

Autosomal Dominant Polycystic Kidney Disease

United States
Kyorin University
Ministry of Health, Labour and Welfare, Japan

Unknown

CCB Safety Study in Treatment of Hypertension of ADPKD

Kidney, Polycystic, Autosomal Dominant

Japan
NYU Langone Health

Completed

High Water Intake to Slow Progression of Polycystic Kidney Disease

Kidney, Polycystic, Autosomal Dominant

United States
Regeneron Pharmaceuticals
Sanofi

Completed

A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene

Hypercholesterolemia

France, United States
Ministry of Health, Labour and Welfare, Japan

Unknown

Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)

Kidney, Polycystic, Autosomal Dominant

Japan
Mario Negri Institute for Pharmacological Research

Recruiting

Outcome of ADPKD With Octreotide LAR (ADPKD648)

Autosomal Dominant Polycystic Kidney

Italy
Mei changlin

Unknown

Radiofrequency Ablation for ADPKD Blood Pressure and Disease Progression Control (RAFALE)

Hypertension | Autosomal Dominant Polycystic Kidney Disease

China
Sanofi

Terminated

Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat (STAGED-PKD-EXT)

Congenital Cystic Kidney Disease

Germany, Spain, United States, Australia, Belgium, Japan, Korea, Republic of, Netherlands
Otsuka Pharmaceutical Development & Commercialization...

Completed

Efficacy and Safety of Tolvaptan in Subjects With Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease

Chronic Kidney Disease | Autosomal Dominant Polycystic Kidney Disease

Australia, Belgium, Italy, Spain, Sweden, United States, Canada, Netherlands, Czechia, Poland, Germany, Russian Federation, Hungary, Israel, Puerto Rico, Argentina, Denmark, South Africa, United Kingdom, Norway, France, Romania
Regulus Therapeutics Inc.

Recruiting

A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

Polycystic Kidney, Autosomal Dominant | Autosomal Dominant Polycystic Kidney Disease | ADPKD

United States
University of Southern California

Enrolling by invitation

Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD-SAT)

Autosomal Dominant Polycystic Kidney Disease

United States
Novartis Pharmaceuticals

Completed

Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease

Autosomal Dominant Polycystic Kidney Disease

Germany, Austria, France
Cantonal Hospital Graubuenden
University of Zurich

Not yet recruiting

Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease (SIDIA)

Autosomal Dominant Polycystic Kidney Disease

Switzerland
Rege Nephro Co., Ltd.

Recruiting

Study of Tamibarotene in Patients With ADPKD

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Japan
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

United States
Weill Medical College of Cornell University
The Rogosin Institute

Enrolling by invitation

Autosomal Dominant Polycystic Kidney Disease Somatic Mutation Biorepository (ADPKD)

Autosomal Dominant Polycystic Kidney Disease

United States
Esther Meijer

Unknown

Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt (WATER)

Polycystic Kidney, Autosomal Dominant | Autosomal Dominant Polycystic Kidney | ADPKD

Netherlands
Medtronic Vascular

Completed

PROTECT Continued Access Post Marketing Surveillance Trial (PROTECT-CA)

Coronary Artery Disease, Autosomal Dominant, 1

United States
Radboud University Medical Center

Recruiting

Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts (ATLAS)

Autosomal Dominant Polycystic Kidney | Polycystic Liver Disease | Liver Cyst | Autosomal Dominant Polycystic Liver Disease

Netherlands
University of Colorado, Denver

Active, not recruiting

Statin Therapy in Patients With Early Stage ADPKD

Autosomal Dominant Polycystic Kidney | ADPKD

United States
Palladio Biosciences
Centessa Pharmaceuticals plc

Terminated

Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ACTION)

Autosomal Dominant Polycystic Kidney | ADPKD

United States, Spain, Hungary, United Kingdom, Australia, Bulgaria, Poland, Turkey
Kadmon, a Sanofi Company

Completed

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD

Autosomal Dominant Polycystic Kidney | ADPKD

United States
Lisbet Brandi

Unknown

Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease (PoCKET)

Autosomal Dominant Polycystic Kidney

Denmark
Kyorin University

Completed

Efficacy Study of Water Drinking on PKD Progression. (ESWP)

Disease Progression | Autosomal Dominant Polycystic Kidney Disease

Japan
University of California, San Francisco

Recruiting

Genetic Testing in Autosomal Dominant Polycystic Kidney Disease

ADPKD

United States
Universitair Ziekenhuis Brussel

Not yet recruiting

Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester? (ADKETONE)

ADPKD

Clinical Trials on Autosomal Dominant Osteopetrosis Type 2

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations